The LATA clinical trial led by University College London researchers has established that eight-weekly long-acting HIV injections of cabotegravir and rilpivirine keep the virus suppressed more effectively than daily antiretroviral tablets among African adolescents, registering a viral rebound rate of just 1 per cent over 96 weeks compared to 6 per cent for those on daily pills. The study tracked 476 participants between the ages of 12 and 19 across clinics in Kenya, South Africa, Uganda, and Zimbabwe, revealing that 94 per cent of those receiving the injections found them vastly easier to manage than a daily pill schedule, thereby alleviating the heavy psychological burden of daily stigma associated with the condition. Principal investigators and trial leads, including Professor Sarah Pett and Dr. Mutsa Bwakura-Dangarembizi, underscored the urgency of making these formulations widely available in Africa—where nearly 90 per cent of HIV-positive adolescents live—since current availability remains severely restricted outside clinical trials despite WHO guidelines recognizing them as a viable alternative. However, expansion efforts are severely hampered by economic and logistical constraints, such as steep manufacturing costs tied to ongoing patents, the logistical hurdle of refrigerating rilpivirine, and the demand for regular nursing supervision, which Dr. Deborah Ford warned could worsen systemic healthcare inequalities if left unaddressed. Backed by sponsors like UCL, funding from the European Union via EDCTP-2, and contributions of trial medicines from Johnson & Johnson and ViiV Healthcare alongside various international research centers, the study serves as a strong call to action for equitable global access to advanced adolescent HIV care.
